Free Trial

Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Here's Why

Pharvaris logo with Medical background

Pharvaris (NASDAQ:PHVS - Get Free Report) saw unusually-high trading volume on Monday . Approximately 189,848 shares were traded during trading, an increase of 157% from the previous session's volume of 73,937 shares.The stock last traded at $16.43 and had previously closed at $16.72.

Analyst Ratings Changes

Separately, Cantor Fitzgerald dropped their price objective on Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th.

Get Our Latest Stock Report on Pharvaris

Pharvaris Trading Down 3.8%

The company's fifty day simple moving average is $15.52 and its 200 day simple moving average is $17.13. The firm has a market capitalization of $869.06 million, a P/E ratio of -5.94 and a beta of -2.86.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.09). On average, analysts predict that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of PHVS. Palumbo Wealth Management LLC purchased a new position in Pharvaris in the 4th quarter worth about $196,000. KLP Kapitalforvaltning AS purchased a new position in shares of Pharvaris during the fourth quarter valued at approximately $111,000. JPMorgan Chase & Co. lifted its position in Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after purchasing an additional 2,847 shares during the period. Geode Capital Management LLC boosted its holdings in Pharvaris by 3.7% in the fourth quarter. Geode Capital Management LLC now owns 38,333 shares of the company's stock worth $735,000 after purchasing an additional 1,356 shares during the last quarter. Finally, FMR LLC boosted its holdings in Pharvaris by 3.6% in the fourth quarter. FMR LLC now owns 5,395,370 shares of the company's stock worth $103,429,000 after purchasing an additional 189,714 shares during the last quarter.

Pharvaris Company Profile

(Get Free Report)

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

Read More

Should You Invest $1,000 in Pharvaris Right Now?

Before you consider Pharvaris, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.

While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA
This Unique Robotaxi Play Could Deliver 10X Returns

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines